Epistem Analytical Protein Services –
Flow Cytometry and Luminex®

Epistem offer protein analysis as a vital readout of Test Item efficacy in vivo and in vitro. Efficacy can be assessed locally at the disease site, for example, in tumours, arthritic joints or inflamed skin, as well as in the draining lymph nodes to the site of inflammation. The ability of a Test Item to elicit systemic responses can also be assessed in the blood (cells or soluble factors) and in secondary lymphoid organs such as the spleen.

At Epistem, we offer 2 automated platforms that can be used to analyse proteins in cells and liquid samples:

Miltenyi MACS Quant Analyser 10 Flow Cytometer

Bio-Rad BioPlex 200 Luminex Analyser

At Epistem, protein readouts have been validated in the following areas:

In vivo

  • Inflammation (Inflammatory Bowel Disease, Arthritis, Psoriasis)
  • Immuno-oncology (syngeneic models)
  • Oncology supportive care (oral and gastrointestinal mucositis)
  • Human skin xenograft (graft rejection)

In vitro

  • Peripheral blood mononuclear cells
  • Differentiated monocytes (dendritic cells, macrophages)
  • Skin (keratinocytes, skin organ culture and co-culture)
  • Cancer cells and cancer stem cells (variety of cell lines)
  • Small intestine organoids

Macs Quant Analyser 10, FACS Machine

  • 3 lasers, 8 fluorescent channels
  • Single tube and 96 well automated acquisition
  • Integrated auto-labelling and functionality to enrich rare cell populations
  • Cell count and viability option
  • 24 hour Remote support
  • Sample carry over 0.01%
Macs Quant Analyser 10, FACS Machine

Cell types analysed at Epistem:

  • Tissue resident (eg. gut, joint, spleen, lymph nodes)
  • Tumour resident
  • Tissue culture
  • Blood
cell types analysed at Epistem

Epistem's FACS service is available as a stand-alone analysis service or as part of a comprehensive integrated pre-clinical package.

Typical endpoints - FACS analysis of typical markers in various therapeutic indications

Typical endpoints - FACS analysis of typical markers in various therapeutic indications.

Bio-Plex 200 system, Luminex platform

  • 2 lasers
  • Distinguishes 100 colour coded beads
  • Limit of analytes to be measured is determined by manufacturer of kits
  • Automated reading of 96 well plates

Epistem has evaluated proteins in:

  • Serum
  • Plasma
  • Cell supernatants
  • Tissue lysates (e.g. gut, skin)
Bio-Plex 200 system, Luminex platform
Typical endpoints – Luminex analysis of cytokines in various disease tissues

Typical endpoints – Luminex analysis of cytokines in various disease tissues.

 

Summary of FACS and Luminex Capabilities

  • Identification and characterisation of immune cells
  • Analysis of antigen-specific T-cells and cytokine-secreting cells
  • Whole blood cell analysis
  • Identification and characterisation of cancer stem cells
  • Cell fate tracking with fluorescent proteins
  • Monitoring cell viability, apoptosis and cell cycle
  • Identification and characterisation of circulating tumour cells
  • Solid tumour cell analysis (post-dissociation)
Summary of FACS and Luminex Capabilities

Get in touch

Find out how Epistem can assist with your research…

* Required Fields

Speak to one of our scientists

About Epistem

Epistem's contract research service is committed to providing reliable, innovative and transferable pre-clinical models and services to support decision making throughout the drug discovery and development pipeline.

Tel: +44 (0)161 850 7600  Email: info@epistem.co.uk